AXA IM Alts raises €1.9b for life sciences investments in Europe

AXA IM Alts has secured €1.9 billion ($2.2 billion) of equity in the past seven months to accelerate investments into the life sciences sector.

The fund was significantly oversubscribed, with capital coming from a range of clients from North America, Asia and Europe.

Life sciences is an emerging but high potential asset class in Europe, supported by a number of economic, demographic and technological changes. The sector is benefitting from significant growth in available public and private funding, according to AXA.

The capital raised will primarily be invested through Kadans Science Partner, a fully integrated developer, owner and operator of European science parks and lab offices, which AXA acquired in December 2020.

Kadans’ portfolio consists of 167,000 square meters (1.8 billion square feet) of operating space across 22 assets in key research locations in the Netherlands, the United Kingdom and Germany, as well as eight developments set to deliver